SCHEMBL5212640

SCHEMBL5212640

N#Cc1ccc(S(=O)(=O)C2(F)CCN(CCc3ccccc3)CC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 10/20 0.66
HTR2A P28223 7/20 0.66
HTR2C P28335 7/20 0.66
DRD2 P14416 4/20 0.66
KCNJ1 P48048 2/20 0.51
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48
CA5A P35218 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA13 Q8N1Q1 1/20 0.48
CA14 Q9ULX7 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
USP2 O75604 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216429 0.90 KCNH2 (0.74) KCNH2HTR2AHTR2CDRD2KCNJ1
SCHEMBL5214013 0.88 HTR2A (0.66) KCNH2HTR2AHTR2CDRD2MEN1
SCHEMBL5209665 0.85 HTR2A (0.67) KCNH2HTR2AHTR2CDRD2MEN1
SCHEMBL5213095 0.85 HTR2A (0.77) KCNH2HTR2AHTR2CDRD2KCNJ1
SCHEMBL5213206 0.81 HTR2A (0.71) KCNH2HTR2AHTR2CDRD2MMP1
SCHEMBL5213445 0.79 HTR2A (1.00) KCNH2HTR2AHTR2CDRD2
SCHEMBL6102337 0.79 HTR2A (0.71) KCNH2HTR2AHTR2CDRD2KCNJ1
SCHEMBL5212442 0.73 HTR2A (0.78) KCNH2HTR2AHTR2CDRD2
SCHEMBL5216044 0.73 HTR2A (0.60) KCNH2HTR2AHTR2CDRD2SMN1; SMN2
SCHEMBL5214395 0.71 HTR2A (0.78) KCNH2HTR2AHTR2CDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211735-A1 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor MERCK SHARP & DOHME LTD. (GB) 2006-09-21 US claimed
EP-1641756-B1 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR MERCK SHARP & DOHME (GB) 2007-04-11 EP disclosed
EP-1240154-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20060211735-A1 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor MERCK SHARP & DOHME LTD. (GB) 2006-09-21 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 KCNH2 4255/4885HTR2A 495/4885HTR2C 1084/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 KCNH2 4221/4885HTR2A 1202/4885HTR2C 1621/4885
US-20060211735-A1 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor HTR2A, HTR2C, HTR5A KCNH2 442/4885HTR2A 1/4885HTR2C 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.